Renalogic News

Kevin Weinstein Joins Renalogic as CEO to Fuel Growth

Media Release

Industry veteran to drive growth for pioneering dialysis risk management and cost containment company.

PHOENIX, AZ and CHICAGO, IL (August 10, 2021) – Renalogic, the industry leader in dialysis risk management and cost containment, announced today the appointment of Kevin Weinstein as Chief Executive Officer. Weinstein will also join the company’s Board of Directors.  Lisa Moody, who served as the company’s Chief Executive Officer since 2009, will assume the role of Chairwoman of the Board of Directors.

“As the company continues to grow, we will benefit from Kevin’s proven ability to lead high-functioning teams that drive results for clients,” Moody said. “Kevin’s experience launching healthcare solutions that challenge the status quo will set a new pace for our accelerated growth.”

Weinstein brings a deep background in successfully growing investor-backed, innovative healthcare companies.  Immediately prior to joining Renalogic, Weinstein was President of population health technology company Azara Healthcare.  Previously he has served as CEO and in other executive positions at a variety of pioneering healthcare companies including Allscripts (NASDAQ: MDRX), ZirMed (now Waystar), and Valence Health (now part of Evolent Health (NYSE: EVH).

“I am pleased to join the Renalogic team, especially now. The industry is shifting, and employers, payers, and at-risk healthcare provider organizations are seeking innovative ways to reduce risk and manage costs,” Weinstein said. “Faced with rapidly increasing chronic kidney disease rates among the US population, health plan fiduciaries are turning to Renalogic’s nearly 20-year history of helping clients and their employees/members manage the risks and costs associated with chronic kidney disease and dialysis.”

Renalogic simultaneously helps clients reduce risk and manage costs by supporting better health outcomes and providing significant savings related to dialysis care. Renalogic’s predictive analytics identify potential risks associated with CKD while the clinically proven Kidney Dialysis Avoidance Program delivers tailored intervention that slows, stops, and in some cases, reverses members’ trajectory toward dialysis.  For those employee/members that do progress to dialysis, the company’s proprietary claims repricing methodology provides net savings of up to 85%, which typically translates to more than $1 million per employee/member.

As part of its commitment to accelerating growth, Renalogic participated in a growth recapitalization with Carrick Capital Partners, which was announced in March 2021.

About Carrick Capital Partners

Headquartered in San Francisco and Newport Beach, Carrick Capital Partners is a buy-out/growth-oriented investment firm that utilizes ABV (Approach to Building Value) to operationally scale fast-growing, technology-enabled businesses. Carrick adds value by taking a concentrated approach and dedicating significant resources post-investment. Leveraging decades of experience, Carrick helps scale great companies that deliver excellent returns for investors, stimulating economic growth, and positively impacting the industry landscape. Working directly with CEOs and entrepreneurs, Carrick fulfills a vital need for investment capital and growth expertise. For more information, please visit http://www.carrickcapitalpartners.com/.

contact us today to learn more.

About Renalogic

Founded in 2002, Renalogic helps self-funded plans of all sizes and their U.S-based health plan members reduce the human and financial costs of chronic kidney disease (CKD) and dialysis treatment. We help plans manage dialysis claims costs and work to prevent members from progressing to dialysis. Through our cost containment and population health management solutions, Renalogic is 230% better than commercial plans at identifying undiagnosed CKD, 86% effective at preventing members from kidney failure and delivers 84.5% average savings off contracted rates with our claims repricing. We’ve saved our clients over $780,000,000 and helped stop CKD from progressing for thousands of members.